NCT00320749View on ClinicalTrials.gov

Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

January 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Capecitabine

Will be give on days 8-21

DRUG

Docetaxel

Will be given on days 1 and 8,

DRUG

Gemcitabine

A fixed dose rate will be give on days 8 and 15.

Trial Locations (2)

43210

Ohio State University, Columbus

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

University of Michigan Rogel Cancer Center

OTHER

lead

Tony Bekaii-Saab

OTHER

NCT00320749 - Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer | Biotech Hunter | Biotech Hunter